Cytological Biomarkers

Cytology have been act as a main tools utilised in the diagnosis of cancer. These techniques have evolved from an era of diagnosis based on haematoxylin and eosin (H&E) stained slides  to the current regular evaluation of tumours by immunocytochemistry (IHC) to confirm tumour histogenesis and subtype. In breast cancer, this means the routine IHC evaluation of hormone receptors (oestrogen and progesterone receptors) as well as evaluation of HER2 expression  and Ki67 (a marker of tumour proliferation). These factors strongly influence prognosis and the selection of anti-cancer treatments.

 

  • cytological carcinoma
  • Cytopathology marker

Related Conference of Cytological Biomarkers

December 07-08, 2020

2nd Asia Pacific Oncology and Cancer Conference

Tokyo, Japan
December 07-08, 2020

International Conference on Cancer and Care

Paris, France
December 10-11, 2020

4th Annual Conference on Skin Cancer and Dermatology

Abu Dhabi, UAE
February 25-26, 2021

5th Global summit on Cancer Science and Oncology

Vienna, Austria
April 05-06, 2021

2 nd Global Summit on Oncology and Hematology

Berlin, Germany
April 28-29, 2021

11th World Congress on Breast Cancer

Barcelona, Spain
May 17-18, 2021

8th World Congress on Epigenetics and Chromosome

Zurich, Switzerland
May 17-18, 2021

11th World Congress on Breast Cancer & Therapies

Prague, Czech Republic
June 23-24, 2021

41st Euro Congress on Cancer Science & Therapy

Barcelona, Spain
July 12-13, 2021

World Congress on Women Oncology & Care

Melbourne, Australia
July 12-13, 2021

Global Immuno-Oncology & Biomarkers Summit

Melbourne, Australia
August 13-14, 2021

2nd World Cancer, Oncology and Therapeutics Congress

Munich, Germany

Cytological Biomarkers Conference Speakers

Recommended Sessions

Related Journals

Are you interested in